Results 81 to 90 of about 4,120 (178)

Therapeutic targeting of PRMT5 and mutant ACVR1 in paediatric glioma

open access: yes, 2021
Diffuse Intrinsic Pontine Glioma (DIPG) is a universally fatal paediatric brainstem tumour with a median overall survival of 9-11 months. The unique genetic, anatomical and developmental identity of the tumour means that there are currently no effective chemotherapies or targeted therapies.
openaire   +1 more source

International physician survey on management of FOP: a modified Delphi study

open access: yesOrphanet Journal of Rare Diseases, 2017
Fibrodysplasia ossificans progressiva (FOP), a disabling disorder of progressive heterotopic ossification (HEO), is caused by heterozygous gain-of- function mutations in Activin receptor A, type I (ACVR1, also known as ALK2), a bone morphogenetic protein
Maja Di Rocco   +12 more
doaj   +1 more source

Co-Crystallisation Of Acvr1 With Three Compounds - Fine Screen

open access: yes, 2018
The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada, Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no.
Adamson, Roslin Jane   +3 more
openaire   +2 more sources

An Activin Receptor IA/Activin-Like Kinase-2 (R206H) Mutation in Fibrodysplasia Ossificans Progressiva

open access: yesCase Reports in Genetics, 2013
Fibrodysplasia ossificans progressiva (FOP) is an exceptionally rare genetic disease that is characterised by congenital malformations of the great toes and progressive heterotopic ossification (HO) in specific anatomical areas. This disease is caused by
Rafael Herrera-Esparza   +7 more
doaj   +1 more source

ACVR1 Crystals at the Diamond Light Source – Beamline I04.

open access: yes, 2019
Funding Acknowledgment: The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen,
Williams, E.P., Bullock, A.N.
openaire   +2 more sources

Molecular Developmental Biology of Fibrodysplasia Ossificans Progressiva: Measuring the Giant by Its Toe

open access: yesBiomolecules
When a genetic disease is characterized by the abnormal activation of normal molecular pathways and cellular events, it is illuminating to critically examine the places and times of these activities both in health and disease.
O. Will Towler   +2 more
doaj   +1 more source

Purification Of Acvr1 Alone And Tgfbr1 (Alk5) Complexed With Fkbp12

open access: yes, 2018
Purifications of ALK2 and ALK5 (the latter in complex with FKBP12) and crystal ...
Adamson, Roslin   +3 more
openaire   +2 more sources

Momelotinib: Mechanism of action, clinical, and translational science

open access: yesClinical and Translational Science
Myelofibrosis is a chronic myeloproliferative disorder characterized by bone marrow fibrosis, splenomegaly, anemia, and constitutional symptoms, with a median survival of ≈6 years from diagnosis.
Georgios Vlasakakis   +8 more
doaj   +1 more source

Another Acvr1 Purification For Fragment Screening And Co-Crystallisation

open access: yes, 2018
A rather unsuccessful purification, but nevertheless, enough for three crystal plates to follow up compound ...
Adamson, Roslin   +3 more
openaire   +1 more source

Poster Sessions

open access: yes
HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Home - About - Disclaimer - Privacy